Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Rhinovirus Infections Drug Market Set To Climb From $1.47 Billion In 2026 To $2.04 Billion By 2030
The rhinovirus infections drug market size has experienced significant expansion in recent years. It is anticipated to grow from $1.36 billion in 2025 to $1.48 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The historical growth can be ascribed to a high incidence of the common cold, limited antiviral options, widespread use of over-the-counter drugs, seasonal infection patterns, and consumer demand for fast relief.
The rhinovirus infections drug market size is projected to expand significantly over the coming years. This market is set to reach $2.05 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the forecast period is fueled by advancements in antiviral research, better viral targeting technologies, increased awareness of respiratory infections, progress in pediatric drug development, and innovations in nasal delivery methods. Key developments expected during this period include increased research into antiviral treatments for the common cold, a greater emphasis on therapies that reduce symptoms, the proliferation of nasal spray formulations, a heightened interest in immune-modulating drugs, and a move towards preventive respiratory healthcare.
Get A Free Sample Report With In-Depth Market Insights:
Rhinovirus Infections Drug Market Growth Momentum: What Factors Are Shaping Demand?
A growing number of respiratory disorders is anticipated to stimulate the expansion of the rhinovirus infections drug market in the coming period. Respiratory disorders are medical conditions that affect the lungs and airways, leading to breathing difficulties such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The rise in these disorders is primarily attributed to increasing air pollution and exposure to occupational hazards, which contribute to the greater prevalence of conditions like asthma, COPD, and pneumonia in affected populations. Rhinovirus infections drugs assist in treating respiratory disorders by targeting viral replication, reducing inflammation, and alleviating symptoms to improve respiratory function. For instance, according to the Office for Health Improvement & Disparities, a UK-based government agency, in June 2025, England recorded 854,922 emergency respiratory-related hospital admissions in the year ending 2024, at a rate of 1,428 per 100,000 people, marking a 7% increase from the previous year. Therefore, the increasing incidence of respiratory disorders is a key driver for growth in the rhinovirus infections drug market.
Rhinovirus Infections Drug Market Segment Breakdown: Which Categories Lead On Revenue?
The rhinovirus infections drug market covered in this report is segmented –
1) By Product: Antivirals, Immunomodulators, Vaccines, Nasal Sprays, Symptomatic Treatments
2) By Patient Age Group: Infants, Children, Adults, Elderly
3) By Route Of Administration: Oral, Intranasal, Injectable
4) By Indication: Common Cold, Asthma Exacerbation, Chronic Obstructive Pulmonary Disease (COPD) Exacerbation, Other Indications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
Subsegments:
1) By Antivirals: Pleconaril, Vapendavir, Rupintrivir, Other Antivirals
2) By Immunomodulators: Interferons, Toll-Like Receptor Agonists, Other Immunomodulators
3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines
4) By Nasal Sprays: Antihistamine Nasal Sprays, Decongestant Nasal Sprays, Steroid Nasal Sprays, Saline Nasal Sprays
5) By Symptomatic Treatments: Analgesics, Antipyretics, Cough Suppressants, Expectorants, Antihistamines
Rhinovirus Infections Drug Market Trends Redefining Industry Growth
Leading companies in the rhinovirus infections drug market are concentrating on creating innovative products, such as antiviral medications, to improve treatment efficacy, lessen symptom severity, and accelerate patient recovery. Antiviral drugs combat viral infections by hindering viral replication within the body. These medications can effectively manage influenza, HIV, hepatitis, and rhinovirus. Some antivirals prevent viruses from entering host cells, while others stop their replication or assembly. For instance, in March 2025, Altesa BioSciences Inc., a US-based biotechnology company, obtained clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir, aimed at treating rhinovirus infections in individuals with COPD. Vapendavir is an oral broad-spectrum antiviral drug that works by preventing rhinovirus from entering and replicating within human cells. It has demonstrated effectiveness against 97% of rhinoviruses and other respiratory enteroviruses. Altesa BioSciences maintains exclusive global rights for the development, manufacturing, and commercialization of vapendavir. The drug is intended to provide targeted treatment for vulnerable populations, including those with COPD and asthma.
Rhinovirus Infections Drug Market Leading Players And Competitive Positioning
Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cocrystal Pharma Inc., Biota Pharmaceuticals Inc., Romark Laboratories L.C., Altamira Therapeutics Ltd., Pneumagen Ltd., AIM ImmunoTech Inc., hVIVO Services Limited, Maxwell Biosciences Inc., Altesa BioSciences Inc., Via Nova Therapeutics Inc., MetP Pharma AG, Ntvirin Pharma, GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Bayer AG, Cipla Limited, Reckitt Benckiser Group plc
View The Full Rhinovirus Infections Drug Market Report:
Rhinovirus Infections Drug Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the rhinovirus infection drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhinovirus infections drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
